121 related articles for article (PubMed ID: 33250293)
41. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
42. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
43. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
44. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.
Shukla S; Zaher H; Hartz A; Bauer B; Ware JA; Ambudkar SV
Pharm Res; 2009 Feb; 26(2):480-7. PubMed ID: 18841445
[TBL] [Abstract][Full Text] [Related]
45. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance.
Beebe J; Zhang JT
J Pharmacol Exp Ther; 2019 Nov; 371(2):320-326. PubMed ID: 31455631
[TBL] [Abstract][Full Text] [Related]
46. ABCG2 as a therapeutic target candidate for gout.
Fujita K; Ichida K
Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
[TBL] [Abstract][Full Text] [Related]
47. Role of ABCG2 in transport of the mammalian lignan enterolactone and its secretion into milk in Abcg2 knockout mice.
Miguel V; Otero JA; García-Villalba R; Tomás-Barberán F; Espín JC; Merino G; Álvarez AI
Drug Metab Dispos; 2014 May; 42(5):943-6. PubMed ID: 24568887
[TBL] [Abstract][Full Text] [Related]
48. Genetic effects of FASN, PPARGC1A, ABCG2 and IGF1 revealing the association with milk fatty acids in a Chinese Holstein cattle population based on a post genome-wide association study.
Li C; Sun D; Zhang S; Yang S; Alim MA; Zhang Q; Li Y; Liu L
BMC Genet; 2016 Jul; 17():110. PubMed ID: 27468856
[TBL] [Abstract][Full Text] [Related]
49. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
[TBL] [Abstract][Full Text] [Related]
50. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
[TBL] [Abstract][Full Text] [Related]
51. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
52. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Klarica Domjanović I; Lovrić M; Trkulja V; Petelin-Gadže Ž; Ganoci L; Čajić I; Božina N
Br J Clin Pharmacol; 2018 Sep; 84(9):2106-2119. PubMed ID: 29791014
[TBL] [Abstract][Full Text] [Related]
53. Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer.
Roh YJ; Kim JH; Kim IW; Na K; Park JM; Choi MG
Mol Cancer Ther; 2017 Aug; 16(8):1487-1496. PubMed ID: 28416605
[TBL] [Abstract][Full Text] [Related]
54. Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2.
Song Y; Hu N; Song X; Yang J
Technol Cancer Res Treat; 2020; 19():1533033820928371. PubMed ID: 32552614
[TBL] [Abstract][Full Text] [Related]
55. ABCG2 requires a single aromatic amino acid to "clamp" substrates and inhibitors into the binding pocket.
Gose T; Shafi T; Fukuda Y; Das S; Wang Y; Allcock A; Gavan McHarg A; Lynch J; Chen T; Tamai I; Shelat A; Ford RC; Schuetz JD
FASEB J; 2020 Apr; 34(4):4890-4903. PubMed ID: 32067270
[TBL] [Abstract][Full Text] [Related]
56. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
57. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
[TBL] [Abstract][Full Text] [Related]
58. Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
Wang L; McNamara PJ
Drug Metab Dispos; 2012 May; 40(5):1018-23. PubMed ID: 22344699
[TBL] [Abstract][Full Text] [Related]
59. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
Tang SC; Sparidans RW; Cheung KL; Fukami T; Durmus S; Wagenaar E; Yokoi T; van Vlijmen BJ; Beijnen JH; Schinkel AH
Clin Cancer Res; 2014 Jun; 20(12):3133-45. PubMed ID: 24727322
[TBL] [Abstract][Full Text] [Related]
60. Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib.
Song YK; Park JE; Oh Y; Hyung S; Jeong YS; Kim MS; Lee W; Chung SJ
J Pharmacol Exp Ther; 2019 Jan; 368(1):79-87. PubMed ID: 30396915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]